Monalizumab (IPH2201) is a humanized monoclonal antibody designed to inhibit the immune checkpoint receptor Natural Killer Group 2A (NKG2A). By blocking NKG2A, Monalizumab enhances interferon-gamma (IFN-??) production, which in turn augments the effector functions of natural killer (NK) cells. This antibody is primarily utilized in research focused on understanding and treating head and neck squamous cell carcinoma (HNSCC).
Monalizumab (IPH2201) is a humanized monoclonal antibody designed to inhibit the immune checkpoint receptor Natural Killer Group 2A (NKG2A). By blocking NKG2A, Monalizumab enhances interferon-gamma (IFN-??) production, which in turn augments the effector functions of natural killer (NK) cells. This antibody is primarily utilized in research focused on understanding and treating head and neck squamous cell carcinoma (HNSCC).
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
